Real-World check: can a targeted ovarian cancer drug deliver outside clinical trials?
Disease control
Not yet recruiting
This study tracks the safety and effectiveness of mirvetuximab soravtansine (MIRV), a drug that targets a protein called folate receptor alpha on cancer cells, in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers will observe 400 patients r…
Sponsor: NING LI-GYN • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC